Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Oncology InstituteTOI -6.98%61 Debt-to-EBITDA is 24.78 as of Mar. 2026. GuruFocus rates TOI with a GF Score™ of 61/100 and a GF Value™ of $2.27 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 478 Healthcare Providers & Services companies, The Oncology Institute ranks worse than 209204.81% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for The Oncology Institute's Debt-to-EBITDA or its related term are showing as below:
TOI'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.59 Med: -1.38 Max: 12.88
Current: -3.59
During the past 8 years, the highest Debt-to-EBITDA Ratio of The Oncology Institute was 12.88. The lowest was -3.59. And the median was -1.38.
TOI's Debt-to-EBITDA is ranked worse than 100% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.25
vs TOI: -3.59
The Oncology Institute (NAS:TOI) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The Oncology Institute Debt-to-EBITDA Related Terms
The Oncology Institute Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for The Oncology Institute's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, The Oncology Institute's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Oncology Institute Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where The Oncology Institute's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
The Oncology Institute (TOI) has a Debt-to-EBITDA of 24.78 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on The Oncology Institute. According to the industry distribution chart, The Oncology Institute ranks #999999 out of 478 companies in the Healthcare Providers & Services industry.
Is The Oncology Institute's Debt-to-EBITDA too high?
The Oncology Institute's current Debt-to-EBITDA is 24.78. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.25. The Oncology Institute's value of 24.78 is 1001.3% above this industry median. Based on the distribution chart, The Oncology Institute ranks #999999 out of 478 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, The Oncology Institute has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does The Oncology Institute's Debt-to-EBITDA compare to CYH and SRTA?
According to the Healthcare Providers & Services industry distribution chart, The Oncology Institute ranks #999999 out of 478 companies for Debt-to-EBITDA. This places The Oncology Institute in the lower half of its industry. The industry median Debt-to-EBITDA is 2.25. The Oncology Institute's value of 24.78 is 1001.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.25, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Oncology Institute's current Debt-to-EBITDA of 24.78 is 1001.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on The Oncology Institute. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Oncology Institute's current Debt-to-EBITDA is 24.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Oncology Institute stock overvalued right now?
Based on GuruFocus' analysis, The Oncology Institute (TOI) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.27, compared to a current price of $5.26 — trading 131.7% above its estimated fair value. The current Debt-to-EBITDA is 24.78 and 1001.3% above the Healthcare Providers & Services industry median of 2.25. The Oncology Institute's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For The Oncology Institute (TOI), the current Debt-to-EBITDA is 24.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Oncology Institute (TOI) Overvalued in 2026?
Based on GuruFocus' analysis, The Oncology Institute stock appears to be overvalued.
The current stock price of $5.26 is trading 131.7% above its estimated GF Value™ of $2.27.
GuruFocus considers The Oncology Institute to be Significantly Overvalued.
Key valuation signals for TOI:
Debt-to-EBITDA: 24.78
GF Value™: $2.27 vs. price of $5.26 (131.7% above fair value)
Industry Position: 1001.3% above the Healthcare Providers & Services median (#999999 of 478)
No single metric tells the full story. See the TOI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
61GF Score
Get the complete analysis for TOI
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TOI has been successfully added to your 
